131 related articles for article (PubMed ID: 30646464)
1. [FREQUENCY AND RISK FACTORS OF SEVERE LIVER DYSFUNCTION IN ISONIAZID MONO-THERAPY FOR LATENT TUBERCULOSIS INFECTION].
Ito K
Kekkaku; 2016 Sep; 91(9):607-616. PubMed ID: 30646464
[TBL] [Abstract][Full Text] [Related]
2. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Gray EL; Goldberg HF
Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
[TBL] [Abstract][Full Text] [Related]
3. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(8):224-9. PubMed ID: 20203555
[TBL] [Abstract][Full Text] [Related]
4. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
[TBL] [Abstract][Full Text] [Related]
5. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
Fresard I; Bridevaux PO; Rochat T; Janssens JP
Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
[TBL] [Abstract][Full Text] [Related]
6. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
7. [Liver dysfunction during treatment of latent tuberculosis infection].
Nakazono T; Tezuka N; Tagawa H; Takayanagi K; Sugita H; Takase A; Yamaguchi T; Shimao T
Kekkaku; 2011 Feb; 86(2):51-5. PubMed ID: 21404650
[TBL] [Abstract][Full Text] [Related]
8. Treatment of latent tuberculosis infection: An update.
Lobue P; Menzies D
Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
[TBL] [Abstract][Full Text] [Related]
9. Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area.
Moon HH; Park SY; Kim JM; Park JB; Kwon CHD; Peck KR; Kim SJ; Lee SK; Joh JW
Ann Transplant; 2017 Jun; 22():338-345. PubMed ID: 28579606
[TBL] [Abstract][Full Text] [Related]
10. Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.
Devrim İ; Devrim F; Bayram N; Aktürk H; Aksay A; Can D; Apa H
Minerva Pediatr (Torino); 2021 Apr; 73(2):184-187. PubMed ID: 26377643
[TBL] [Abstract][Full Text] [Related]
11. [Treatment outcome of latent tuberculosis infection in persons with fibrotic pulmonary lesions].
Komukai J; Matsumoto K; Kudoh S; Okado A; Yoshiyama T; Yoshida H; Shimouchi A
Nihon Koshu Eisei Zasshi; 2021 Jun; 68(6):405-411. PubMed ID: 33790095
[TBL] [Abstract][Full Text] [Related]
12. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review.
Kunst H; Khan KS
Int J Tuberc Lung Dis; 2010 Nov; 14(11):1374-81. PubMed ID: 20937175
[TBL] [Abstract][Full Text] [Related]
13. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection.
Miyazawa S; Matsuoka S; Hamana S; Nagai S; Nakamura H; Nirei K; Moriyama M
Intern Med; 2015; 54(6):591-5. PubMed ID: 25786447
[TBL] [Abstract][Full Text] [Related]
15. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.
Bliven EE; Podewils LJ
Int J Tuberc Lung Dis; 2009 Sep; 13(9):1054-60. PubMed ID: 19723392
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for isoniazid hepatotoxicity in children with latent TB and TB: difference from adults.
Devrim I; Olukman O; Can D; Dizdarer C
Chest; 2010 Mar; 137(3):737-8. PubMed ID: 20202962
[No Abstract] [Full Text] [Related]
17. [Liver damage in treatment of latent tuberculous infection by isoniazid].
Ito K; Hoshino H; Nakazono T; Masuyama H; Sugita H; Yoshiyama T; Kato S
Kekkaku; 2006 Nov; 81(11):651-60. PubMed ID: 17154043
[TBL] [Abstract][Full Text] [Related]
18. Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy.
Sung YK; Cho SK; Kim D; Won S; Choi CB; Kim TH; Jun JB; Yoo DH; Bae SC
Korean J Intern Med; 2018 Sep; 33(5):1016-1024. PubMed ID: 28288508
[TBL] [Abstract][Full Text] [Related]
19. Is isoniazid safe for liver transplant candidates with latent tuberculosis?
Stucchi RS; Boin IF; Angerami RN; Zanaga L; Ataide EC; Udo EY
Transplant Proc; 2012 Oct; 44(8):2406-10. PubMed ID: 23026607
[TBL] [Abstract][Full Text] [Related]
20. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.
Fountain FF; Tolley E; Chrisman CR; Self TH
Chest; 2005 Jul; 128(1):116-23. PubMed ID: 16002924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
